ISI

Report: Biomarkers market will hit $19.86 billion in 2015

Tuesday, June 28, 2011 02:39 PM

A new report from visiongain, a London-based business information provider, predicts the global biomarkers market will be worth $19.86 billion in 2015.

More... »

Health Decisions creates ‘fixed-price trial’ model to incentivize CRO performance and speed timelines

Monday, June 27, 2011 08:03 AM

Since CROs began conducting trials for drug sponsors, there has been a lot of quibbling about cost. CROs claim to do the work more quickly, efficiently and inexpensively. But many sponsors have had the opposite experience, saying CROs don’t accomplish recruitment goals and keep extending the trial timelines to do so, adding to the sponsor’s costs. Some claim not all of the data is collected properly, taking months to then clean the data, for which sponsors are charged.

More... »

More sites turn to clinical trials portals, dashboards to improve management and communication

Monday, June 13, 2011 07:53 AM

As sponsors and CROs feel the pressure to improve clinical trial efficiency, increase enrollment and maintain a solid bottom line, it’s critical that they avoid information overload while measuring the right performance indicators as data from multiple sources is streamlined.

More... »

Isis Pharmaceuticals reports phase I study results

Tuesday, March 8, 2011 10:39 AM

Isis Pharmaceuticals announced the results from a phase I clinical trial in which ISIS-CRPRx produced statistical reductions in C-reactive protein (CRP) in the cohort with elevated CRP.  ISIS-CRPRx was well tolerated at doses up to 600 mg/week.  Isis plans to evaluate ISIS-CRPRx in phase II studies in indications that could provide early proof-of-concept in diseases with elevated CRP.  Isis plans to initially evaluate ISIS-CRPRx in multiple myeloma and rheumatoid arthritis, and then move to cardiovascular and other diseases.

More... »

Health Decisions receives Safe Harbor certification

Tuesday, March 1, 2011 11:47 AM

Durham, N.C.-based Health Decisions, a CRO in adaptive clinical trials, has received Safe Harbor Certification, effective Feb. 15, 2011.

More... »

Oracle to Acquire Phase Forward for $685M

Friday, April 16, 2010 02:37 PM

Business software giant Oracle, already a player in the eClinical space, plans to acquire market leader Phase Forward in a deal valued at approximately $685 million—or $17 per share in cash.

More... »

BioClinica, Health Decisions Broaden CRO Networks

Thursday, March 18, 2010 07:42 AM

BioClinica added two contract research organizations (CROs)—Health Sciences International and PRL Central Laboratory Services—to its Certified Partner Program, a group established by the CRO to broaden its service offerings. 

More... »

Health Decisions Adds Klixar to Network

Thursday, December 3, 2009 08:20 AM

Durham, N.C.-based Health Decisions, a full-service CRO specializing in high-efficiency adaptive solutions, announced that Argentina-based CRO Klixar has joined its Agile Clinical Network—a newly launched community of research partners formed to eliminate the information gaps and prolonged timelines of complex global studies.

More... »

ISI Acquires Apyx to Bolster Services

Wednesday, November 18, 2009 08:18 AM

Whippany, N.J.-based ISI, a provider of software and services for the life sciences industry, has acquired Apyx in an effort to boost ISI’s services business.

More... »

LabConnect Hires Former Quintiles Exec to be COO

Friday, August 28, 2009 07:32 AM

LabConnect, a provider of central laboratory services to the clinical trial industry, appointed former Quintiles executive Frank Morrow, Ph.D., as its chief operating officer.

More... »